Alpha 2.0
Login Register
» Authors » B Coudert

B Coudert

Explore the profile of B Coudert including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 91
Citations 1361
Followers 0
Related Specialties
Oncology
Dentistry
Pulmonary Medicine
Top 10 Co-Authors
L Arnould
P Fumoleau
L Jeannin
P Foucher
P Camus
P Fargeot
J M Riedinger
J Guerrin
S Guiu
C Focan
Published In
Bull Cancer
Ann Oncol
Br J Cancer
Eur J Cancer
Inf Dent
Affiliations
Soon will be listed here.
Recent Articles
11.
Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based study
Dabakuyo T, Arnaud A, Maingon P, Causeret S, Coudert B, Fumoleau P, et al.
Eur J Cancer Care (Engl) . 2013 May; 22(5):638-47. PMID: 23647444
This population-based study aimed to describe the effects of neoadjuvant chemotherapy (NC) on survival in breast cancer (BC) patients in daily practice. BC patients treated with NC followed by surgery...
12.
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis
Giacchetti S, Dugue P, Innominato P, Bjarnason G, Focan C, Garufi C, et al.
Ann Oncol . 2012 Jun; 23(12):3110-3116. PMID: 22745214
Background: Molecular circadian clocks can modify cancer chemotherapy effects, with a possible moderation according to sex differences. We investigated whether sex determine the optimal delivery schedule of chemotherapy for metastatic...
13.
Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching
Le Ray I, Dabakuyo S, Crehange G, Bardou M, Arnould L, Fraisse J, et al.
Eur J Cancer . 2012 Apr; 48(15):2300-10. PMID: 22513230
Background: Even though neoadjuvant chemotherapy has shown no benefits on overall survival (OS), it is being widely used in the treatment of breast cancer. This is based on the assumption...
14.
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes
Humbert O, Berriolo-Riedinger A, Riedinger J, Coudert B, Arnould L, Cochet A, et al.
Ann Oncol . 2012 Apr; 23(10):2572-2577. PMID: 22499859
Background: The aim of this study is to evaluate the impact of the different breast cancer subtypes on the tumor (18)F-FDG uptake at baseline and on its changes after the...
15.
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival
Ladoire S, Arnould L, Mignot G, Apetoh L, Rebe C, Martin F, et al.
Br J Cancer . 2011 Jul; 105(3):366-71. PMID: 21750556
Background: In HER2-overexpressing breast cancer, accumulating preclinical evidences suggest that some chemotherapies, like trastuzumab, but also taxanes, are able to trigger a T helper 1 (Th1) anticancer immune response that...
16.
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Borget I, Cadranel J, Pignon J, Quoix E, Coudert B, Westeel V, et al.
Eur Respir J . 2011 Jun; 39(1):172-9. PMID: 21659409
Several clinical and biological parameters are known to influence the efficacy of second-line erlotinib therapy for nonsmall cell lung cancer (NSCLC), but their medico-economic impact has not been evaluated. The...
17.
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
Coudert B, Ciuleanu T, Park K, Wu Y, Giaccone G, Brugger W, et al.
Ann Oncol . 2011 May; 23(2):388-94. PMID: 21610154
Background: In the placebo-controlled phase III SATURN study, maintenance erlotinib after first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) and overall survival (OS) in the overall study population of patients...
18.
p53 gene alterations are associated with a decreased responsiveness to neoadjuvant chemotherapy in human breast cancer
Lizardnacol S, Coudert B, Riedinger J, Fargeot P, Guerrin J
Int J Oncol . 2011 May; 10(6):1203-7. PMID: 21533505
Recent evidence indicates that alterations of the p53 tumor suppressor gene can modulate the response of tumor cells to DNA-damaging agents and increase drug resistance. To evaluate whether p53 alterations...
19.
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
Guiu S, Gauthier M, Coudert B, Bonnetain F, Favier L, Ladoire S, et al.
Br J Cancer . 2010 Oct; 103(9):1335-42. PMID: 20978512
Background: We analysed whether the level of human epidermal growth factor receptor-2 (HER-2) amplification significantly influenced either pathological complete response (pCR) or recurrence-free survival (RFS) and overall survival (OS) after...
20.
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy
Guiu S, Liegard M, Favier L, Van Praagh I, Largillier R, Weber B, et al.
Ann Oncol . 2010 Aug; 22(2):321-8. PMID: 20693300
Background: Very effective trastuzumab-based primary systemic therapy (PST) can be proposed for conservative surgery purpose to human epidermal growth factor receptor 2 (HER2)-positive breast cancer (HER2+BC). Long-term follow-up (LTFU) warrants...